"Treatment strategies could be tailor-made for these women based on their genetic make-up and how susceptible it makes them to breast cancer recurrence," said Damaraju, the journal Public Library of Science ONE reports.
The kit, which is being developed in Canada, focuses on something called luminal A breast cancer - the most common form of the disease and the type generally thought to have the best prognosis, according to the Daily Mail.
However, with it making up around 60 percent of the 50,000 cases of breast cancer diagnosed each year, it still accounts for a substantial number of relapses and deaths.
Alberta researchers tested blood samples taken from women when they had been diagnosed with breast cancer years previously.
